Phase i trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

Investigational New Drugs

Volumn 27, Issue 5, 2009, Pages 453-460

  Sanborn, Sharon L ^a   Gibbons, Joseph ^b   Krishnamurthi, Smitha ^b   Brell, Joanna M ^b   Dowlati, Afshin ^b   Bokar, Joseph A ^b   Nock, Charles ^b   Horvath, Nancy ^b   Bako, Jacob ^b   Remick, Scot C ^c   Cooney, Matthew M ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Anti angiogenic; Docetaxel; Lenalidomide; Phase i

Indexed keywords

ACETYLSALICYLIC ACID; DOCETAXEL; LENALIDOMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLADDER CANCER; BLEEDING; BONE MARROW SUPPRESSION; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FLATULENCE; FLUSHING; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HEADACHE; HEMATURIA; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; INSOMNIA; LEUKOPENIA; LIVER FUNCTION TEST; LUNG CANCER; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; SALIVARY GLAND DISEASE; SARCOMA; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; TASTE; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; URINARY FREQUENCY; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; TAXOIDS; THALIDOMIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349234247     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9200-x     Document Type: Article

References (60)

1. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D
2. AL Harris 1997 Antiangiogenesis for cancer therapy Lancet 349 13 15 10.1016/S0140-6736(97)90014-3 1:CAS:528:DyaK2sXjs1yls7c%3D doi:10.1016/S0140- 6736(97)90014-3
3. RK Jain 2005 Antiangiogenic therapy for cancer: current and emerging concepts Oncology 19 7 16 15934498 Williston Park
4. RS Kerbel 1991 Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents Bioessays 13 31 36 1722975 10.1002/bies.950130106 1:STN:280:DyaK387is1SitQ%3D%3D doi:10.1002/bies.950130106
5. G Klement S Baruchel J Rak, et al. 2000 Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 R15 R24 10772661 10.1172/JCI8829 1:CAS:528:DC%2BD3cXisFOlurc%3D doi:10.1172/JCI8829
6. T Browder CE Butterfield BM Kraling, et al. 2000 Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878 1886 10766175 1:CAS:528:DC%2BD3cXisVynurk%3D
7. J Folkman 1995 Clinical applications of research on angiogenesis N Engl J Med 333 1757 1763 7491141 10.1056/NEJM199512283332608 1:STN:280: DyaK28%2Fpt1ejuw%3D%3D doi:10.1056/NEJM199512283332608 (Pubitemid 26009687)
8. RS Kerbel 2000 Tumor angiogenesis: past, present and the near future Carcinogenesis 21 505 515 10688871 10.1093/carcin/21.3.505 1:CAS:528: DC%2BD3cXitVeit7w%3D doi:10.1093/carcin/21.3.505
9. FA Scappaticci 2002 Mechanisms and future directions for angiogenesis-based cancer therapies J Clin Oncol 20 3906 3927 12228212 10.1200/JCO.2002.01.033 1:CAS:528:DC%2BD38XntVynsLs%3D doi:10.1200/JCO.2002.01. 033 (Pubitemid 35050846)
10. CA Hudis 2005 Clinical implications of antiangiogenic therapies Oncology 19 26 31 15934500 Williston Park
11. BA Teicher 1999 Combination of antiangiogenic agents with standard cytotoxic therapies in therapeutic regimens Clin Cancer Res 5 3878s 3879s
12. SL Sanborn MM Cooney A Dowlati, et al. 2008 Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles Invest New Drugs 26 355 362 18470481 10.1007/s10637-008-9137-0 1:CAS:528: DC%2BD1cXnsVKiu7o%3D doi:10.1007/s10637-008-9137-0
13. K Dredge JB Marriott CD Macdonald, et al. 2002 Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects Br J Cancer 87 1166 1172 12402158 10.1038/sj.bjc.6600607 1:CAS:528:DC%2BD38XotFWrurk%3D doi:10.1038/sj.bjc.6600607 (Pubitemid 35418112)
14. PG Richardson RL Schlossman E Weller, et al. 2002 Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 3063 3067 12384400 10.1182/blood-2002-03- 0996 1:CAS:528:DC%2BD38XosVSis78%3D doi:10.1182/blood-2002-03-0996 (Pubitemid 35217050)
15. D Belotti V Vergani T Drudis, et al. 1996 The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1843 1849 9816139 1:CAS:528:DyaK28Xnt1SitLo%3D
16. KA Hotchkiss AW Ashton J Sparano, et al. 2000 Inhibition of endothelial cell function by docetaxel (Taxotere) Proc Am Assoc Cancer Res 41 647
17. CJ Sweeney KD Miller SE Sissons, et al. 2001 The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 3369 3372 11309294 1:CAS:528:DC%2BD3MXjtFSjur4%3D
18. CJ Sweeney SE Sissions S Nozaki, et al. 2000 Overcoming resistance to the anti-angiogenic properties of docetaxel induced by endothelial cell stimulation Proc Am Assoc Cancer Res 41 647
19. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D doi:10.1093/jnci/92.3.205
20. RS Kerbel 1997 A cancer therapy resistant to resistance Nature 390 335 336 9389468 10.1038/36978 1:CAS:528:DyaK2sXnslSjtrg%3D doi:10.1038/36978 (Pubitemid 28027292)
21. L Bello G Carrabba C Giussani, et al. 2001 Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo Cancer Res 61 7501 7506 11606386 1:CAS:528:DC%2BD3MXnvFShsLc%3D
22. G Klement P Huang B Mayer, et al. 2002 Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts Clin Cancer Res 8 221 232 11801563 1:CAS:528:DC%2BD38XhsVKlsrs%3D
23. S Man G Bocci G Francia, et al. 2002 Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water Cancer Res 62 2731 2735 12019144 1:CAS:528:DC%2BD38XjvFSmsbg%3D
24. K Pietras D Hanahan 2005 A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J Clin Oncol 23 939 952 15557593 10.1200/JCO.2005.07.093 1:CAS:528: DC%2BD2MXit1Ggu7k%3D doi:10.1200/JCO.2005.07.093 (Pubitemid 46202314)
25. N Takahashi A Haba F Matsuno, et al. 2001 Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide Cancer Res 61 7846 7854 11691802 1:CAS:528:DC%2BD3MXotlaku70%3D
26. BA Teicher EA Sotomayor ZD Huang 1992 Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease Cancer Res 52 6702 6704 1384969 1:CAS:528:DyaK3sXjt1Gnug%3D%3D
27. T Vogt C Hafner K Bross, et al. 2003 Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors Cancer 98 2251 2256 14601096 10.1002/cncr.11775 1:CAS:528:DC%2BD3sXps1ars7k%3D doi:10.1002/cncr.11775 (Pubitemid 37392430)
28. K Spieth R Kaufmann J Gille 2003 Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pre-treated advanced melanoma: a pilot study Cancer Chemother Pharmacol 52 377 382 12879280 10.1007/s00280-003-0678-9 1:CAS:528:DC%2BD3sXotFWmtLs%3D doi:10.1007/s00280-003- 0678-9 (Pubitemid 37363610)
29. C Hafner A Reichle T Vogt 2005 New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy Curr Cancer Drug Targets 5 393 419 16178816 10.2174/1568009054863591 1:CAS:528: DC%2BD2MXovFSjs7w%3D doi:10.2174/1568009054863591 (Pubitemid 41176178)
30. DF McDermott DC Cho JR Merchan, et al. 2006 A phase II pilot trial of low dose, continuous infusion, or "metronomic", paclitaxel and oral celecoxib in patients with metastatic melanoma Proc Am Assoc Cancer Res 24 8010
31. SD Young M Whissell JC Noble, et al. 2006 Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors Clin Cancer Res 12 3092 3098 16707607 10.1158/1078-0432.CCR-05-2255 1:CAS:528: DC%2BD28Xks1Citb0%3D doi:10.1158/1078-0432.CCR-05-2255 (Pubitemid 43837356)
32. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D doi:10.1056/NEJMoa072113
33. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D doi:10.1056/NEJMoa032691 (Pubitemid 38702844)
34. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI doi:10.1056/ NEJMoa061884 (Pubitemid 44917502)
35. JB Bartlett A Michael IA Clarke, et al. 2004 Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers Br J Cancer 90 955 961 14997189 10.1038/sj.bjc.6601579 1:CAS:528:DC%2BD2cXhslWrs7o%3D doi:10.1038/sj.bjc.6601579 (Pubitemid 38495811)
36. K Dredge R Horsfall SP Robinson, et al. 2005 Orally administered lenalidomide (CC-5013) in anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvasc Res 69 56 63 15797261 10.1016/j.mvr.2005.01.002 1:CAS:528:DC%2BD2MXis1Gqtrc%3D doi:10.1016/j.mvr.2005. 01.002 (Pubitemid 40410468)
37. A List 2007 Lenalidomide-the phoenix rises N Engl J Med 357 2183 2186 18032768 10.1056/NEJMe078203 1:CAS:528:DC%2BD2sXhtlGisLjP doi:10.1056/ NEJMe078203 (Pubitemid 350146115)
38. SV Rajkumar SR Hayman MQ Lacy, et al. 2005 Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 106 4050 4053 16118317 10.1182/blood-2005-07-2817 1:CAS:528:DC%2BD2MXhtlaltrzN doi:10.1182/blood-2005-07-2817 (Pubitemid 41775908)
39. M Dimopoulos A Spencer M Attal, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123 2132 18032762 10.1056/NEJMoa070594 1:CAS:528:DC%2BD2sXhtlGis7nN doi:10.1056/NEJMoa070594 (Pubitemid 350146107)
40. DM Weber C Chen R Niesvizky, et al. 2007 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133 2142 18032763 10.1056/NEJMoa070596 1:CAS:528:DC%2BD2sXhtlGis7bM doi:10.1056/ NEJMoa070596 (Pubitemid 350146108)
41. A List G Dewald J Bennett, et al. 2006 Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456 1465 17021321 10.1056/NEJMoa061292 1:CAS:528:DC%2BD28XhtVGgtrvO doi:10.1056/ NEJMoa061292 (Pubitemid 44511560)
42. A List S Kurtin DJ Roe, et al. 2005 Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 549 557 15703420 10.1056/NEJMoa041668 1:CAS:528:DC%2BD2MXhtFemsrc%3D doi:10.1056/NEJMoa041668 (Pubitemid 40204668)
43. TE Witzig J Vose D Pietronigro, et al. 2007 Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma Proc Am Assoc Cancer Res 25 8066
44. PH Wiernik IS Lossos J Tuscano, et al. 2007 Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma Proc Am Assoc Cancer Res 25 8052
45. AY Bedikian K Kim N Papadopoulos, et al. 2007 Preliminary results from a phase I/II study of the combination of lenalidomide and DTIC in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy Proc Am Assoc Cancer Res 25 8533
46. MM Zhang JK Chan A Husain, et al. 2007 Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma Gynecol Oncol 105 194 198 17257661 10.1016/j.ygyno.2006.11.026 1:CAS:528:DC%2BD2sXjsVemsLo%3D doi:10.1016/j.ygyno.2006.11.026 (Pubitemid 46441459)
47. R Dreicer J Garcia S Smith, et al. 2007 Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC) Proc Am Assoc Cancer Res 25 15515
48. TK Choueiri R Dreicer BI Rini, et al. 2006 Phase II study of lenalidomide in patients with metastatic renal cell carcinoma Cancer 107 2609 2616 17075879 10.1002/cncr.22290 1:CAS:528:DC%2BD28XhtlCmu7jJ doi:10.1002/cncr.22290 (Pubitemid 44845615)
49. PH Patel GV Kondagunta L Schwartz, et al. 2008 Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma Invest New Drugs 26 273 276 18161005 10.1007/s10637-007-9107-y 1:CAS:528:DC%2BD1cXkvFyjsLo%3D doi:10.1007/s10637-007-9107-y
50. JM Shammo M Kassar I Robin, et al. 2007 A case report of sarcoma regression in a patient with MDS treated with lenalidomide Proc Am Assoc Cancer Res 25 20535
51. TM Tohnya J Gulley P Arlene, et al. 2006 Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer Proc Am Assoc Cancer Res 24 13038
52. RA Sharma WP Steward CA Daines, et al. 2006 Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies Eur J Cancer 42 2318 2325 16899362 10.1016/j.ejca.2006.05.018 1:CAS:528:DC%2BD28Xptlykt78%3D doi:10.1016/j.ejca.2006.05.018 (Pubitemid 44307625)
53. Moss RA, Mohile SG, Shelton G et al (2007) A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). ASCO Prostate Cancer Symposium 89
54. S Kalmadi M Davis A Dowlati, et al. 2007 Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors Invest New Drugs 25 211 216 17103043 10.1007/s10637-006- 9025-4 1:CAS:528:DC%2BD2sXltlartrs%3D doi:10.1007/s10637-006-9025-4 (Pubitemid 46774699)
55. GH Lyman AA Khorana A Falanga, et al. 2007 American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 5490 5505 17968019 10.1200/JCO.2007.14.1283 1:CAS:528:DC%2BD1cXnvVChtA%3D%3D doi:10.1200/JCO.2007. 14.1283 (Pubitemid 350232226)
56. WL Dahut JL Gulley PM Arlen, et al. 2004 Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 2532 2539 15226321 10.1200/JCO.2004.05.074 1:CAS:528:DC%2BD2cXpsVWks7w%3D doi:10.1200/JCO.2004.05.074 (Pubitemid 41103740)
57. M Zangari E Anaissie B Barlogie, et al. 2001 Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Blood 98 1614 1615 11520815 10.1182/blood.V98.5.1614 1:CAS:528:DC%2BD3MXmvFGjur8%3D doi:10.1182/blood.V98.5.1614
58. C Angelotta AJ Lurie AJ Lurie, et al. 2006 Black box warning on lenalidomide-associated venous thromboembolism (VTE) in off-label setting: A preemptive and unusual safety initiative Proc Am Assoc Cancer Res 24 6074
59. CL Bennett C Angelotta PR Yarnold, et al. 2006 Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer JAMA 296 2558 2560 17148721 10.1001/jama.296.21.2558-c 1:CAS:528:DC%2BD28Xht12lsbnJ doi:10.1001/jama.296.21.2558-c
60. E Horstmann MS McCabe L Grochow, et al. 2005 Risks and benefits of phase 1 oncology trials, 1991 through 2002 N Engl J Med 352 895 904 15745980 10.1056/NEJMsa042220 1:CAS:528:DC%2BD2MXhvFOhtrc%3D doi:10.1056/NEJMsa042220 (Pubitemid 40300298)